483
Lilly France S.A.S.Lilly France S.A.S. – FDA 483, Sep 29, 2022
Record Details
This FDA Form 483 report details significant deficiencies at Lilly France SAS in Fegersheim, France, a drug product manufacturer. Observations primarily concern inadequate written procedures, ineffective contamination prevention, deviations from validated parameters, and poor facility maintenance. These issues indicate a moderate level of severity regarding GMP compliance for sterile drug product manufacturing.
View Company Profile
ID · 041c69f4-4312-492a-881f-670b2cd26c17
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.